Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma

Sandra Iurescia, Daniela Fioretti, Pasquale Pierimarchi, Emanuela Signori, Manuela Zonfrillo, Giancarlo Tonon, Vito M. Fazio, Monica Rinaldi

Research output: Contribution to journalArticle

Abstract

Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the VHCDR3109-116 epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.

Original languageEnglish
Article number316069
JournalJournal of Biomedicine and Biotechnology
Volume2010
DOIs
Publication statusPublished - 2010

Fingerprint

DNA Vaccines
Immunization
Lymphoma
Vaccination
Vaccines
Immunity
Neoplasms
DNA
B-Cell Lymphoma
Immunotherapy
Epitopes
B-Lymphocytes
Growth
Therapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Genetics
  • Molecular Biology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)

Cite this

Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. / Iurescia, Sandra; Fioretti, Daniela; Pierimarchi, Pasquale; Signori, Emanuela; Zonfrillo, Manuela; Tonon, Giancarlo; Fazio, Vito M.; Rinaldi, Monica.

In: Journal of Biomedicine and Biotechnology, Vol. 2010, 316069, 2010.

Research output: Contribution to journalArticle

Iurescia, Sandra ; Fioretti, Daniela ; Pierimarchi, Pasquale ; Signori, Emanuela ; Zonfrillo, Manuela ; Tonon, Giancarlo ; Fazio, Vito M. ; Rinaldi, Monica. / Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. In: Journal of Biomedicine and Biotechnology. 2010 ; Vol. 2010.
@article{a560da27953f4d07a2147920a96580b9,
title = "Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma",
abstract = "Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the VHCDR3109-116 epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.",
author = "Sandra Iurescia and Daniela Fioretti and Pasquale Pierimarchi and Emanuela Signori and Manuela Zonfrillo and Giancarlo Tonon and Fazio, {Vito M.} and Monica Rinaldi",
year = "2010",
doi = "10.1155/2010/316069",
language = "English",
volume = "2010",
journal = "Journal of Biomedicine and Biotechnology",
issn = "1110-7243",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma

AU - Iurescia, Sandra

AU - Fioretti, Daniela

AU - Pierimarchi, Pasquale

AU - Signori, Emanuela

AU - Zonfrillo, Manuela

AU - Tonon, Giancarlo

AU - Fazio, Vito M.

AU - Rinaldi, Monica

PY - 2010

Y1 - 2010

N2 - Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the VHCDR3109-116 epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.

AB - Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the VHCDR3109-116 epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=77952493879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952493879&partnerID=8YFLogxK

U2 - 10.1155/2010/316069

DO - 10.1155/2010/316069

M3 - Article

C2 - 20445751

AN - SCOPUS:77952493879

VL - 2010

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

SN - 1110-7243

M1 - 316069

ER -